Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Vehicle-Controlled, First-in-Human Safety, Tolerability and Proof-of-Concept Study of Topical ATR12-351 in Adults With Netherton Syndrome

Next Previous
Trial Profile

A Randomized, Double-Blind, Vehicle-Controlled, First-in-Human Safety, Tolerability and Proof-of-Concept Study of Topical ATR12-351 in Adults With Netherton Syndrome

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATR 12 (Primary)
  • Indications Netherton Syndrome
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Azitra

Most Recent Events

  • 17 Jun 2025 According to an Azitra media release, The trial is halfway enrolled, as six patients have been dosed with ATR12-351 and company will discuss the Phase 1b trial for ATR12-351 targeting Netherton syndrome in its presentation at the BIO International Convention in Boston, Massachusetts. Azitra's presentation is scheduled for 12:00PM ET, on June 17, 2025, in Room 154 of the Boston Convention & Exhibition Center.
  • 17 Jun 2025 Results presented in the Azitra Media Release.
  • 10 Jun 2025 According to an Azitra media release, recent updates form this trial will be presented at the 2025 BIO International Convention.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top